Working… Menu
Trial record 41 of 1005 for:    BMD

Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02958202
Recruitment Status : Terminated (Regulatory approval was not obtained for drisapersen, hence BioMarin is stopping the development of all exon skipping oligonucleotides in DMD.)
First Posted : November 8, 2016
Last Update Posted : January 26, 2018
Information provided by (Responsible Party):
BioMarin Pharmaceutical

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : September 2016
Actual Study Completion Date : September 2016
Certification/Extension First Submitted : January 23, 2018